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Abstract Murine hematopoietic progenitor cells synthesize 
substantial amounts of histamine in response to IL-3 or calcium 
ionophore. They also take up extracellular histamine by an active 
transport system. In the present study we demonstrate that this 
system mediates both influx and efflux of histamine. Indeed, 
MR16155 and thioperamide, the two 1-13 antagonists which are 
most effective in inhibiting histamine uptake, likewise diminish 
the release of preloaded histamine from bone marrow cells. These 
compounds also inhibit the release of histamine which has been 
newly synthesized by hematopoietic progenitors in response to 
IL-3 or calcium ionophore, as assessed by the accumulation of 
the mediator inside the cells in the presence of the antagonists. 
The potency of different histamine receptor antagonists as 
inhihitors of histamine release increases with their capacity to 
block histamine uptake. 
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Histamine uptake is temperature-dependent and partially 
requires sodium exchange [13]. Although we have provided 
evidence that this phenomenon is not mediated by classical 
histamine receptors, Ha receptor antagonists, uch as thioper- 
amide and MR16155, are potent inhibitors. Conversely to the 
polyamine transport system, which exists in numerous cell 
types and has been extensively studied [14,15], histamine 
transport seems to be restricted to astrocytes, endothelial 
and glial cells, and is still poorly understood [16-18]. It has 
been suggested that astrocytes could use the same means of 
transport for histamine uptake and release [18]. Herein, we 
provide evidence for a bidirectional transporter in bone mar- 
row cells (BMC) and in the IL-3-dependent cell line FDCP1, 
as assessed by the finding that the inhibitors of histamine 
uptake likewise decrease release of preloaded histamine. We 
also show that this system is involved in the release of endo- 
genous histamine which is newly synthesized in response to 
IL-3 or calcium ionophore since we found a decrease in his- 
tamine release accompanied by an increase in intracellular 
histamine contents in the presence of H3 receptor antagonists. 
1. Introduction 2. Materials and methods 
Histamine, a ubiquitous messenger in cell to cell commu- 
nication, has been mainly studied for its role in hypersensitiv- 
ity and in neural transmission [1,2]. The notion that it might 
also affect hematopoiesis originated from experiments show- 
ing that exogenous histamine could induce proliferation and/ 
or differentiation of hematopoietic progenitors [3,4]. In sup- 
port of the physiological relevance of these findings, we have 
demonstrated several years ago that large amounts of hista- 
mine are generated by murine hematopoietic progenitors upon 
stimulation with interleukin-3 and granulocyte-macrophage- 
colony stimulating factor [5-7]. Furthermore, we established 
that endogenous histamine is requisite for IL-3-induced CFU- 
S cell cycling [8]. 
Most of the biological activities exerted by histamine are 
mediated by either of the three membrane receptor subtypes 
H1, H2 and H3, characterized sofar [9,10]. More recently, two 
additional binding sites, termed intracellular histamine recep- 
tors (Hie), have been identified in the mierosome and in the 
nucleus [11,12]. The existence of these receptors, together with 
our recent evidence for histamine uptake by hematopoietic 
progenitors [13], is consistent with the idea that histamine 
does indeed play a physiological role inside hematopoietic 
progenitor cells. 
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2.1. Animals 
Male or female 6-8-week-old C57BL/6 mice bred in our own facil- 
ities under specific pathogen-free conditions, were used in all experi- 
ments. 
2.2. Chemicals and drugs 
Histamine dihydrochloride was purchased from Sigma (St. Louis, 
MO). Thioperamide and MR16155 were donated by Bioprojet 
(Marne la Coquette, France). a-Fluoromethylhistidine (aFMH) was 
a gift from Merck Sharp and Dohme Research Laboratories (Rah- 
way, N J). 
2.3. Cell preparations 
Bone marrow cells were removed from femurs and tibiae by flush- 
ing with ice-cold Hanks' balanced salt solution (HBSS; Gibco, Grand 
Island, NY). After centrifugation, all cells were suspended in mini- 
mum essential medium (MEM; Gibco) containing 10% horse serum 
(Flobio, Courbevoie, France), 1% sodium pyruvate 100 x, 1% nones- 
sential amino acids, 100 IU/ml penicillin, and 100 Ixg/ml streptomycin 
(all from Gibco; referred to as culture medium). The IL-3-dependent 
FDCP1 cell line was grown in RPMI containing 10% fetal calf serum 
(Gibco) and 10% WEHI-conditioned medium as a source of IL-3. 
2.4. Histamine uptake 
Total bone marrow cells (107/ml) were suspended in MEM, con- 
taining 10 -4 M histamine together with 5 × 10-SM a-FMH (irrever- 
sible inhibitor of histidine decarboxylase (HDC: EC 4.1.1.22), which 
prevents endogenous histamine synthesis) with or without various 
compounds at indicated concentrations. They were incubated for 3 
h in polystyrene tubes (Falcon 2003), centrifuged, and washed twice 
in HBSS. Pelleted cells were lysed in 0.4 N perchloric acid, and in- 
tracellular histamine was measured in lysates by an automated con- 
tinuous flow fluorometric technique previously described [19]. The 
lower limit of sensitivity of this assay is about 0.5 ng/ml. 
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2.5. Histamine effiux 
Total bone marrow cells (107/ml) or FDCP1 cells (5×106 /ml) 
suspended in culture medium were preloaded for 3 h or 30 rain, 
respectively, with 10 -4 M histamine in the presence of 5×10 -5 M 
ct-FMH. After two successive washings, cells were incubated at 
2.5X106 per ml with various chemicals. At indicated times ceils 
were centrifuged, washed, and intracellular histamine contents deter- 
mined. 
2.6. Histamine synthesis 
Total bone marrow cells (2.5 X 106/ml) were incubated for 24 h in 
culture medium in the presence of 1 ng/ml IL-3 (R&D, Abingdon, 
UK)  or 5 )< 10 -7 M calcium ionophore (Boehringer, Mannheim, Ger- 
many) with or without he indicated compounds. Histamine concen- 
trations in supernatants and pellets were determined as mentioned 
above. 
2.7. Statistical analysis 
Results are presented as means + S.E.M. of n experiments. Statisti- 
cal significance was assessed by Student's t-test for paired variants. 
3. Results and discussion 
We have previously established that hematopoietic progeni- 
tor cells from murine bone marrow have the capacity to take 
up substantial mounts of extracellular histamine, which ac- 
cumulates inside the cells [13]. This histamine transport is 
partially dependent on the presence of an electrochemical 
Na + gradient and strongly inhibited by MR16155 and thio- 
peramide. These compounds have been described as specific 
Ha histamine receptor antagonists. Yet, we could demonstrate 
that they do not inhibit histamine uptake via Ha receptor 
blockade [13]. It was therefore plausible that hematopoietic 
progenitor cells possessed a means of histamine transport, 
as described for a few other cell types such as astrocytes, 
endothelial nd glial cells [16-18]. 
In the present study, we addressed the question of whether 
the histamine transporter present in bone marrow cells could 
function in two directions, i.e. take up histamine from the 
extracellular space when required and mediate its release 
from hematopoietic progenitors when it is generated inside 
the cells. To this end, we preloaded bone marrow cells for 3 
h in the presence of 10 -4 M histamine. Under these conditions 
the intracellular histamine contents rose from 100_ + 10 to 
2080+220 pg/106 cells (n= 5). We then washed the cells ex- 
tensively and incubated them in histamine-free medium. As 
ilj, ,, i- 
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Fig. 1. Changes in intracellular histamine contents in the presence 
of MR16155 or thioperamide. (A) Total bone marrow cells, pre- 
loaded with 100 gM histamine for 3 h, were suspended in fresh 
medium and intracellular histamine l vels were determined atdiffer- 
ent time points under control (37°C) conditions (E2), low tempera- 
ture conditions (e), with 1 gM MR16155 ([]) or 1 gM thioperamide 
(A). (B) FDCP1 cells were exposed for 30 min to 100 p.M hista- 
mine. After washing, intracellular histamine l vels were determined 
(to). Changes in histamine contents were then evaluated after a 30 
min incubation in histamine-free ctflture medium at 4°C, 37°C, with 
1 ~M MR16155 (MR) or 1 gM thioperamide (TP). *p<0.05 vs 
control at 37°C (n--5). 
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Fig. 2. Effect of MR16155 on extra- and intracellular histamine 
levels generated by BMC. Total bone marrow cells were incubated 
for 24 h in medium alone (stippled bars), with IL-3 (1 ng/ml) 
(cross-hatched bars) or calcium ionophore (5x 10 -7 M) (hatched 
bars) with or without MR16155 (1 gM). (A) Histamine production 
in supernatants. (B) Intracellular histamine l vels in BMC. *p < 0.05 
vs columns without MR16155 (n = 5). 
shown in Fig. 1A, the amine underwent rapid effiux since 
within 60 min its contents decreased from 2080+220 to 
900 + 80 pg/106 cells and continued to decrease more slowly 
after 2 h. Concomitantly, histamine l vels were augmented in
the extracellular compartment (data not shown). Like hista- 
mine uptake [13], histamine release was abolished at low tem- 
peratures and inhibited by MR16155 (1 gM) or thioperamide 
(1 gM), the most potent inhibitors of histamine uptake (Fig. 
1A). 
Knowing that the cells involved in histamine uptake belong 
to the immature compartment of the bone marrow, we ver- 
ified whether similar results could be obtained using the IL-3 
dependent cell line FDCP1. The latter represents a homoge- 
neous population of hematopoietic progenitors arrested at a 
relatively early stage of differentiation, i  contrast to the het- 
erogeneous bone marrow cells. As shown in Fig. 1B, these 
cells are also capable of histamine uptake and release, both 
inhibited by MR16155, thioperamide, aswell as low tempera- 
tures. Yet, the kinetics are more rapid since influx and efflux 
are maximal within 30 min. 
These data support he notion that hematopoietic progeni- 
tors possess a histamine transport system with bidirectional 
functions, the inward and outward currents being specifically 
blocked by the same inhibitors (MR16155 and thioperamide). 
With regard to the mechanism involved, it is conceivable that 
these compounds have a better affinity for the transporter 
than histamine itself, thus preventing it from crossing the 
membrane. Among the few reports on histamine uptake by 
other cell types [16-18,20,21], only astrocytes seem to be cap- 
able of releasing histamine by a common mechanism related 
to ionic exchanges. The effect of known histamine receptor 
antagonists in this context has not been studied [18]. 
We have previously shown that IL-3 promotes increased 
histamine synthesis by hematopoietic progenitors. Most of 
the newly generated histamine is released, though the intracel- 
lular histamine contents is also consistenly increased [5]. The 
fact that these cells are identical with those capable of hista- 
mine uptake [13] prompted us to verify whether inhibitors of 
histamine uptake also affected the release of endogenous his- 
tamine from bone marrow cells. We found that MR16155 
strongly inhibited IL-3-induced histamine production, as 
shown in Fig. 2A. Similar inhibition was observed when 
bone marrow cells were stimulated with the calcium iono- 
phore A23187, which is also a potent inducer of histamine 
production, as we have shown before [22]. In both situations, 
the decrease in histamine l vels in bone marrow supernatants 
in the presence of MR16155 was accompanied by a striking 
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Fig. 3. Effect of histamine receptor antagonists on IL-3-induced his- 
tamine production by hematopoietic progenitors. Total bone mar- 
row ceils were incubated with IL-3 for 24 h in the presence of the 
following antagonists: MR16155 ([]), thioperamide (A), cimetidine 
(©), lupitidine (n) and cetirizine (e). Histamine was assayed in the 
supernatants (A) and inside the cells (B). Data represent one typical 
experiment out of two. 
increase in intracellular histamine contents (Fig. 2B). It should 
be noted that intracellular histamine levels were already sig- 
nificantly increased in cells cultured in medium alone. 
Furthermore, IL-3-induced histamine concentrations in cell 
supernatants were even more strikingly decreased by 
MR16155 or thioperamide when histamine-producing cells 
were enriched from total bone marrow by fractionation on 
a discontinous Ficoll gradient (data not shown). This decrease 
was also concomitant with increased intracellular histamine 
contents. 
In addition to MR16155 and thioperamide, various other 
histamine receptor antagonists inhibit histamine uptake by 
bone marrow cells with low efficiency [13]. We assayed them 
on histamine fflux and found a good correlation between the 
capacity of a given compound to inhibit histamine uptake and 
its ability to decrease the release of histamine synthesized in
response to IL-3. Indeed, as shown in Fig. 3, the most potent 
inhibitors of histamine uptake (MR16155, IC50 = 14 + 3.6 nM 
and thioperamide, IC50=78.9+17 nM) were also the best 
blockers of histamine release, as assessed by the significant 
increase in intracellular histamine contents. Lupitidine, which 
inhibits histamine uptake at very high doses (IC50 =7+0.3 
gM), also required higher concentrations to inhibit histamine 
release, while cimetidine and cetirizine, which have very little 
effect if any on histamine uptake, did not modify IL-3-induced 
histamine production whatever the dose used (up to 10 -5 M). 
These findings argue in favor of a common mechanism ac- 
counting for histamine influx and efflux in hematopoietic pro- 
genitors. It is also noteworthy that the total histamine produc- 
tion which comprises both extracellular and intracellular 
histamine, was significantly diminished in the presence of 
MR16155 (41.69+2.22 vs 72.33+4.90 rig/106 cells, n=9). 
This diminution might be the result of a feed-back mechanism 
regulating histamine synthesis when high intracellular levels 
are attained. 
This is reminiscent of the very sophisticated regulation of 
polyamine biosynthesis. Indeed, polyamines which are impor- 
tant modulators of cell proliferation and differentiation [23], 
are taken up by the cells similarly to histamine. It has been 
demonstrated that the activity of ornithine decarboxylase 
(ODC), the rate-limiting enzyme of the polyamine cascade, 
is regulated by intracellular polyamine concentrations in var- 
ious ways, namely inhibition of translation, acceleration of 
ODC degradation and induction of an ODC-inhibitory pro- 
tein named antizyme [24,25]. Knowing that both polyamines 
and histamine may play an important role during cell prolif- 
eration and/or differentiation, and that their synthesis by 
ODC and HDC respectively, is induced in hematopoietic or- 
gans by the same growth factors [7,26-28], we are actually 
investigating whether similar mechanisms regulate HDC and 
ODC activities. 
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